Market intelligence
All coverage
Novavax, Inc. announced that its partners secured regulatory clearance for the XFG-adapted Nuvaxovid vaccine in the United States, European Union and Japan. Shares dipped…
Regulatory clearance is complete; royalties now depend on partner-led demand.
| Revenue channel | Economics | What changed |
|---|---|---|
| Sanofi royalties | High teens–low 20s % of global net sales | U.S. and EU seasonal approvals enable sales |
| Takeda | Royalties plus annual approval milestones | Japan approval supports 2026–2027 season |
| Sanofi supply | Recorded as product sales | Commercial supply planned this season |
| Technology transfer | $75M potential milestone | Expected mid-2027 |
Excludes Sanofi supply sales, royalties and milestones.
Versus $751M at Dec. 31, 2025
| Q2 2026 | Value | Year-over-year |
|---|---|---|
| Total revenue | $57M | −76% |
| Product sales | $19M | +76% |
| Net loss | $53M | vs. $107M profit |
| Net R&D expense | $48M | −34% |
| SG&A expense | $27M | −39% |
+47% from $9.00
| High | $19.00 |
| Low | $7.00 |
| Ratings | 2 Buy · 1 Hold · 1 Sell |
Approvals remove regulatory risk, but the stock's muted reaction signals demand uncertainty. The core sensitivities are vaccine uptake, coverage policy, Sanofi execution and timing of royalty recognition. Management gives no Sanofi sales forecast.
Sources: Novavax Aug. 28 approval update and Aug. 6 financial results; Reuters Aug. 27 FDA report; Google Finance. Prices are delayed U.S. quotes at 11:58 EDT on Aug. 28, 2026.
FingerMotion, Inc. shares surged over threefold on Friday, following the announcement of a modular artificial-intelligence data-center plan with BlueFlare Energy Solutions. The move boosted…
The market priced an AI-infrastructure plan before contracts.
| Measure | Figure | Status |
|---|---|---|
| Lyken.AI ownership | 9.9% | Acquired |
| FNGR shares issued | 1,674,480 | Restricted |
| Cash paid | $0 | Equity-funded |
| B300 nodes | 128 | Nonbinding MOU |
The rally values execution that has not occurred. No site, power, customer or project-financing agreement is definitive. The Lyken customer memorandum is nonbinding. Equity consideration dilutes holders, while micro-cap liquidity can reverse quickly.
Illustrative milestone completion: strategy disclosed; four core contractual steps remain.
Sources: FingerMotion announcement and June 8-K; Aug. 28 filing summary; market data at 11:26:07 EDT. Implied prior market cap and value added are calculations from current market cap and the 261.7% price move. Not investment advice.
ASHBURN, Virginia, August 28, 2026, 07:51 — Shares in Quoin rose 41.8% after the company reported QRX003 achieved its primary endpoint, while a $50…
QRX003 Phase 2/3 interim data · Market data at 07:34 EDT, August 28, 2026
Four patients achieved at least a one-grade IGA improvement. The study is open-label and plans about 20 evaluable participants.
| Interim cutoff | 6 patients |
| Treatment duration | 12 weeks |
| Recruitment completion | End-2026 |
| Full topline data | Q2 2027 |
| Regulatory status | Investigational |
QRX003 has U.S. Orphan Drug, Rare Pediatric Disease and Fast Track designations. None guarantees approval.
| Security | Count | Price |
|---|---|---|
| ADSs / pre-funded equivalents | 6.31M | $4.88 |
| Ordinary warrants | 3.15M | $6.10 |
| Existing ADSs | 2.01M | — |
$30.8M upfront; another $19.2M depends on investors exercising warrants.
Simplified ADS-equivalent calculation; excludes other outstanding options and warrants.
The trial crossed its adjusted statistical hurdle and reported no treatment-related serious adverse events. That improved the perceived probability of clinical success.
The financing simultaneously removed a near-term cash constraint. Yet the new ADS equivalents can make existing holders a much smaller share of the company.
Premarket quote
$7.31
Placement price
$4.88 · 33.2% discount
Warrant exercise
$6.10 · 16.6% below quote
June cash + investments: $10.8MQ2 net loss: $5.37MUpfront raise: $30.8M
Management expects full financing proceeds to fund operations into the second half of 2029.
Six-patient sampleOpen-label designFull cohort pendingRegulatory riskDilutionWarrant overhang
A positive interim endpoint can weaken or disappear as enrollment grows.
Sources: Quoin August 28 clinical and financing releases; June-quarter results; StockAnalysis premarket quote. Calculations use ADS equivalents and may differ due to rounding.
BioXcel Therapeutics Inc. dropped nearly 62% ahead of Friday's session following the company's decision to seek Chapter 11 bankruptcy protection. The move changes a…
Chapter 11 turns a pipeline valuation into a recovery waterfall.
Commercial revenue remained small relative to losses. Before court protection, available cash represented roughly 1.5 quarters of the cited operating burn.
Shares of Elastic N.V. jumped 19.7% following an earnings report that surpassed expectations on Thursday. The rise boosted its market capitalization by roughly $1.7…
| Metric | Q1 FY2027 | Change / reference |
|---|---|---|
| Total subscription revenue | $449M | +15% |
| Sales-led subscription revenue | $399M | +18% |
| Total RPO | $1.854B | +27% |
| Net expansion rate | ~111% | Stable expansion signal |
| Non-GAAP operating margin | 16.2% | $77M income |
| GAAP operating margin | -5.0% | $24M loss |
Consensus: 24 analysts. Targets may reset after the earnings release.
Hyperliquid Strategies shares jumped on Thursday after the crypto treasury company reported $305.5 million of annual net income. Most of that profit came from…
CAMBRIDGE, Massachusetts, August 27, 2026, 10:15 Moderna stock slid 5.0% on Thursday, shaving $3.0 billion off its market value, after the company announced a…
Intraday snapshot: August 27, 2026, 10:15:13 EDT
The stock recovered from its session low but remained 5.0% below Wednesday’s close.
The market erased about $2.97 billion while Moderna proposed $2.0 billion of base financing.
| Term | Current disclosure |
|---|---|
| Security | Senior unsecured convertible notes |
| Maturity | 2032 |
| Regular interest | None |
| Purchaser option | $300M for 13 days |
| Settlement | Cash, shares or both |
| Capped-call threshold | At least 150% premium at pricing |
| Metric | Amount | Read-through |
|---|---|---|
| Cash + investments | $6.9B | June 30 |
| Q2 operating cash outflow | $526M | Base notes = 3.8× |
| Q2 net loss | $782M | Base notes = 2.6× |
| July settlement payment | $950M | Post-quarter cash use |
| 2026 year-end cash guide | $4.7B–$5.2B | Before new deal update |
23 analysts · average target $104.53
Target dispersion is wide after the oncology-data rally. The financing terms now add a separate dilution and balance-sheet variable.
The financing converts part of the recent oncology revaluation into liquidity. No regular coupon limits cash interest, but conversion can expand the share count. The capped call only protects up to its final cap.
Pricing: conversion rate, premium and net proceeds.
Hedging: capped-call cost and counterparties’ trading.
Use of funds: oncology investment versus debt repayment.
Risk trigger: weaker clinical or regulatory progress after leverage rises.
Sources: Moderna August 27 financing announcement; Moderna July 31 quarterly results; Google Finance; MarketScreener. Calculations use the $142.20 share price and $56.54 billion market capitalization observed at 10:15:13 EDT on August 27, 2026. Values are rounded.
Volato Group, Inc. jumped 55.31% on Wednesday as the firm announced a merger with Alignment Engine. The private AI-infrastructure company was valued at about…
| Metric | Figure | Signal |
|---|---|---|
| Q2 revenue | $0.965M | Small base |
| Q2 net loss | −$2.051M | Loss exceeds revenue |
| Cash | $8.440M | June 30 |
| H1 operating cash use | −$2.855M | Funding need remains |
| H1 financing cash | +$6.953M | Mostly equity-linked |
| Analyst consensus | None | Zero current ratings |
| Ownership | Undisclosed conversion economics can dilute common holders. |
| Funding | Campus buildout costs and capital sources remain undisclosed. |
| Commercial proof | No campus customers, revenue or contracted backlog were reported. |
| Execution | The path from 154 MW to 480 MW needs permits, equipment and financing. |
| Liquidity | Extreme turnover and the premarket reversal imply high volatility. |
PALO ALTO, August 27, 2026, 06:49 EDT — HP shares dropped 10.6% in premarket trade after the company reported that global PC shipments declined…
| Metric | Result | Reference |
|---|---|---|
| Revenue | $15.7B | +12.5% YoY |
| Adjusted EPS | $0.83 | $0.69 LSEG |
| Personal Systems revenue | $11.8B | +18% YoY |
| PC units | −16% | Consumer −19% |
| Personal Systems margin | 4.6% | 5.2% in Q2 |
| Printing revenue | $3.9B | −2% YoY |
| Quarterly free cash flow | $1.6B | $0.8B in Q2 |
Bars are scaled for visual comparison, not to a common unit. Basis points measure one-hundredth of a percentage point.
The stated 74-cent midpoint includes an estimated eight-cent tariff refund. Removing it leaves 66 cents, one cent below consensus.
| Premarket equity value | ≈$24.95B |
| Close P/E | 11.65× |
| Dividend yield at close | 3.93% |
| Average analyst target | $27.88 |
| Fresh targets, Aug. 27 | Goldman $22 · UBS $28 |
| Consensus | Hold |
Premarket equity value equals $27.28 multiplied by 914.52M shares. Analyst data updated Aug. 27 at 06:45 EDT.
Downside mechanism: memory and storage inflation outpaces repricing, pushing Personal Systems margin below 4.6%.
Upside mechanism: premium and AI-PC mix supports price while shipment declines moderate.
Invalidation check: strip tariff refunds from EPS before comparing core execution with consensus.
PLEASANTON, California, August 26, 2026, 17:41 EDT — Veeva Systems advanced 8.2%, adding $3.3 billion in market capitalization, after the company raised its sales…
The after-hours value gain is about twice Veeva’s $1.6 billion annual adjusted operating-cash-flow guide.
| Metric | Prior | New | Change |
|---|---|---|---|
| Revenue midpoint | $3.640B | $3.6845B | +$44.5M |
| Adjusted operating income | ≈$1.610B | ≈$1.640B | +$30M |
| Adjusted EPS | ≈$9.05 | ≈$9.21 | +$0.16 |
| Adjusted operating cash flow | — | ≈$1.600B | 43% margin |
| Signal | Latest | Growth / status |
|---|---|---|
| R&D and Quality subscription | $419.4M | +19% |
| Commercial subscription | $347.4M | +13% |
| Vault CRM customers live | >180 | 5 top-20 live |
| Top-20 CRM commitments | 12 of 20 | 2 added in August |
| Falcon early adopters | 5 | Initial go-lives due in 2026 |
| Average target | $251.04 · 5.6% below |
| Median target | $266 · 0.3% upside |
| Target range | $165–$340 |
| Pre-report FY2027 EPS estimate | $9.06 |
| New company EPS guide | $9.21 |
Analyst snapshot dated August 26, 2026; comparisons use the 17:40:48 EDT after-hours price.
SAN FRANCISCO, August 26, 2026, 16:49 EDT — Okta's stock climbed 15.7%, boosting its market capitalization by $3.5 billion as the company reported an…
The market added almost four times the raised full-year free-cash-flow midpoint. Sustained backlog conversion is now the central valuation test.
| Metric | Prior midpoint | New midpoint | Change |
|---|---|---|---|
| Revenue | $3.195B | $3.221B | +$26M |
| Adjusted operating income | $816M | $835M | +$19M |
| Adjusted EPS | $3.83 | $3.92 | +$0.09 |
| Free cash flow | $870M | $920M | +$50M |
| Ratings | 46 |
| Buy / Overweight / Hold | 29 / 6 / 9 |
| Underweight / Sell | 2 / 0 |
| Average target | $147.18 · 5.3% below |
| Median target | $161 · 3.6% upside |
| Target range | $75–$180 |
Analyst recommendations and targets as of the August 26, 2026 close.
India's family-SUV market gets two hybrid options with MG's Hector Tomahawk. The brand's battery-rental scheme further shifts car ownership costs towards a subscription model.
| Metric | EV | PHEV |
|---|---|---|
| Battery | 69.2kWh | 20.5kWh |
| Electric range | 517km | 115km |
| Combined range | — | 1,100km+ |
| BaaS rental | ₹4.90/km | ₹3.20/km |
| Delivery start | September | November |
EV BaaS cuts entry cost 28.2%; PHEV BaaS cuts it 15.2%. At 10,000km per year, rentals add ₹49,000 and ₹32,000.
| JSW MG 2025 sales | 70,500 vehicles |
| Growth vs. 2024 | +15.6% |
| Current annual capacity | 120,000 |
| Planned annual capacity | 300,000 |
| Planned investment | $330m–$440m |
| FY2025 venture loss | $121m |
| Close / daily move | CN¥10.39 / +0.78% |
| Volume | 32.57m shares |
| Market value | CN¥117.79bn |
| Trailing revenue | CN¥655.8bn |
| Trailing net income | CN¥10.11bn |
| Trailing P/E | 11.6× |
| Next earnings date | Aug. 29, 2026 |
| Checkpoint | Timing | Signal |
|---|---|---|
| EV registrations | September | Search interest converting into paid deliveries |
| PHEV handovers | November | Demand for long-range hybrid packaging |
| Localization | 2026–2027 | Lower FX and freight exposure |
| Capacity ramp | Multi-year | Utilization against 300,000-unit target |
Bath & Body Works shares pointed down after the company’s quarterly outperformance was largely driven by a tariff refund. Bath & Body Works, Inc.…
Premarket snapshot: August 26, 2026, 07:12 EDT · Earnings data: quarter ended August 1, 2026
Stores still generated 74.7% of quarterly revenue. Direct and international growth offset about 46% of the $65 million store-sales decline.
| FY26 metric | May 27 | Aug. 26 | Change |
|---|---|---|---|
| Net-sales growth | −4.5% to −2.5% | −4.0% to −2.5% | Low end +0.5 pt |
| Adjusted EPS | $2.40-$2.65 | $2.60-$2.80 | Midpoint +6.9% |
| Adjusted gross margin | ~42.4% | ~43.3% | +90 bps |
| Free cash flow | ~$600M | ~$650M | +$50M |
| Capital spending | ~$270M | ~$240M | −$30M |
| Equity value | ~$3.48B |
| FY26 adjusted P/E | ~6.4× midpoint |
| FY26 free-cash-flow yield | ~18.7% |
| Annual dividend yield | ~4.6% |
| 52-week range | $14.28-$32.32 |
Calculated with $17.27, 201.56 million shares, $2.70 adjusted EPS midpoint and $650 million free-cash-flow guidance. No repurchases are assumed in management's outlook.
| Date | Firm | View | Target |
|---|---|---|---|
| Aug. 19 | Telsey | Hold | $22 |
| Aug. 18 | JPMorgan | Neutral | $24 |
| Aug. 18 | Citi | Buy | $25 |
| Jul. 8 | Goldman Sachs | Sell | $19 |
Consensus: Hold from 18 analysts; average target $25.33. Targets may change after the earnings call.
The report beat the company's guidance even after removing the refund. The valuation question is whether direct and international growth can offset a store channel that still supplies three-quarters of sales. The third-quarter guide keeps that test unresolved.
Sources: Bath & Body Works Q2 2026 earnings release and presentation; Yahoo Finance quotation at 07:12 EDT; StockAnalysis analyst record. Price data are indicative and may be delayed. Calculations are derived from disclosed inputs and rounded.
CrowdStrike Holdings, Inc. slipped 2.78% to $185.38 on Tuesday. The cybersecurity firm lagged a 0.66% gain in the Nasdaq Composite ahead of its fiscal…
The range is based on Tuesday’s close and an 8% options-implied move through week-end. It describes expected volatility, not a forecast of direction.
| Metric | Reference | Investor test |
|---|---|---|
| Revenue | $1.436B–$1.442B | Hold or beat midpoint |
| Adjusted EPS | $0.29 estimate | Post-split basis |
| ARR | $5.793B–$5.795B | Fresh bookings matter |
| Non-GAAP operating income | $345.6M–$349.1M | About 24.1% margin |
The Q2 midpoint implies roughly 11% more net new ARR than Q1. Reported balance rounding makes this calculation approximate.
| Company | Aug. 25 close | Daily move | Forward P/E | Analyst target upside |
|---|---|---|---|---|
| CrowdStrike CRWD | $185.38 | −2.78% | 146.1× | +13.6% |
| Palo Alto Networks PANW | $339.90 | −3.13% | 89.6× | +6.7% |
| Zscaler ZS | $168.42 | −4.34% | 39.7× | +18.0% |
| Fortinet FTNT | $153.66 | +1.10% | 43.4× | +4.7% |
Peer weakness makes earnings-specific attribution difficult. CrowdStrike’s premium multiple raises the bar for guidance and contracted subscription growth.
The options range can overstate or understate the actual reaction. A headline revenue beat may not support the shares if ARR, net new bookings or guidance disappoint. Conversely, stronger contracted revenue and margins could outweigh a modest earnings miss. The after-hours market is also thinner than the regular session.
NEW YORK, August 25, 2026, 17:25 EDT - West Texas Intermediate crude declined 3.1%, settling at $82.36 a barrel, as expectations of increased supply…
Price and ETF figures as of August 25, 2026 close, EDT.
EIA estimates. Bypass capacity: about 4.7 million b/d through Saudi and UAE pipelines.
| Signal | Likely crude effect | Why |
|---|---|---|
| Limited sanctions enforcement | Bearish premium | No immediate barrel loss |
| Temporary shipping corridor | Bearish premium | Improves tanker access |
| Secondary sanctions on buyers | Bullish risk | Threatens export demand |
| Retaliation or traffic loss | Bullish risk | Constrains physical flows |
EIA July 2026 forecast. Brent's August 25 settlement is 8.0% above the agency's 2026 average forecast.
Producers: lower spot prices reduce near-term revenue leverage.
Consumers and transports: cheaper fuel can support margins.
Rates: lower energy inflation can ease yield pressure.
Risk: physical disruption can reverse the entire move quickly.
EHang Holdings Limited dropped 9.90% to $4.68 on Tuesday. The autonomous aircraft manufacturer pulled its 2026 revenue outlook following a significant quarterly sales miss.
Market snapshot: August 25, 2026, 14:48 EDT · Regular session
Q1 plus Q2 revenue totaled RMB103.6M. Reaching the former target would have required RMB496.4M in the second half, or RMB248.2M per quarter—3.19× Q2 revenue.
52-week range: $4.57–$20.20. The stock is 76.8% below the high.
Day range $4.57–$5.25
Tuesday's low matched the 52-week floor.
| Metric | Q2 2026 | Comparison |
|---|---|---|
| Revenue | RMB77.9M | +203.5% QoQ; −31.3% YoY |
| eVTOL deliveries | 36 | 4 QoQ; 52 YoY |
| Gross margin | 61.2% | 61.5% YoY |
| Operating loss | RMB131.7M | 169% of revenue |
| Cash and investments | RMB929.4M | ≈7 quarters of Q2 operating loss |
| View | Target |
|---|---|
| High | $11.10 |
| Average | $7.12 |
| BofA · Sell · Aug. 25 | $5.10 |
| Low | $4.40 |
Five ratings: 1 Buy, 2 Hold, 2 Sell.
| Stock | Snapshot | Move |
|---|---|---|
| EHang | 14:48 EDT | −9.90% |
| Archer Aviation | 13:35 EDT | −1.56% |
| Joby Aviation | 13:13 EDT | +0.97% |
The gap points to a company-specific earnings and guidance shock, not a broad eVTOL selloff.
EHang delivered 35 EH216-series aircraft and one VT35. It also sold 520 GD4.0 formation drones. Broader products diversify revenue, but passenger approvals remain the central valuation driver.
Q2 aircraft deliveries were 69.2% of the year-earlier level.
Trial operations at Guangzhou and Hefei have run for 17 months. Management now needs regulatory visibility sufficient to restore a measurable sales forecast.
Regulatory delays can push paid passenger service further out, weaken aircraft deliveries and extend cash consumption. The 61.2% gross margin does not offset an operating loss larger than revenue. Upside requires evidence that overseas sandboxes and non-passenger products can bridge the missing China approval schedule.
Sources: EHang Q2 release dated August 25, 2026; Google Finance market and analyst data captured August 25, 2026; same-session Joby and Archer snapshots captured between 13:13 and 13:35 EDT. Calculations use displayed figures and may differ because of rounding.
